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Abstract
Background: Recent data indicate the Signal Transducer and Activator of Transcription 3 (STAT3) pathway is required for
VEGF production and angiogenesis in various types of cancers. STAT3 inhibitors have been shown to reduce tumor
microvessel density in tumors but a direct anti-angiogenic activity has not been described.
Methodology/Principal Findings: We investigated the direct action of a small molecule inhibitor of STAT3 (LLL12) in human
umbilical cord vascular endothelial cells (HUVECs) in vitro, in a Matrigel model for angiogenesis in vivo, and its antitumor
activity in a xenograft model of osteosarcoma. LLL12 (100 nM) significantly inhibited VEGF-stimulated STAT3
phosphorylation in HUVECs, reduced their proliferation/migration and inhibited VEGF-induced tube formation. Morphologic
analysis of LLL12 treated HUVECs demonstrated marked changes in actin/tubulin distribution and bundling. In scid mice,
LLL12 reduced microvessel invasion into VEGF-infused Matrigel plugs by ,90% at a dose of 5 mg/kg daily. Following a
period of tumor progression (2 weeks), LLL12 completely suppressed further growth of established OS-1 osteosarcoma
xenografts. Pharmacodynamic studies showed robust phosphorylated STAT3 in control tumors, whereas phospho-STAT3
was not detected in LLL12-treated OS-1 tumors. Treated tumors demonstrated decreased proliferation (Ki67 staining), and
decreased microvessel density (CD34 staining), but no significant increase in apoptosis (TUNEL staining), relative to controls.
Assay of angiogenic factors, using an antibody array, showed VEGF, MMP-9, Angiopoietin1/2, Tissue Factor and FGF-1
expression were dramatically reduced in LLL12-treated tumors compared to control tumors.
Conclusions: These findings provide the first evidence that LLL12 effectively inhibits tumor angiogenesis both in vitro and
in vivo.
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Introduction
Signal Transducer and Activator of Transcription 3 (STAT3)
belong to the STAT family of transcription factors. Compelling
evidence has now established that aberrant STAT3 is a molecular
abnormality that has a critical role in the development and
progression of not only adult but also some pediatric tumors [1–4].
In addition to its diverse biological functions including roles in cell
proliferation, differentiation, apoptosis, inflammation, and onco-
genesis, accumulating evidence suggests that STAT3 also plays an
important role in cancer angiogenesis under both physiological
and pathological situations [5–7]. There is accumulating evidence
that STAT3 [8] is an important facilitator of tumor angiogenesis
and its activation correlates with VEGF production in a variety of
human cancers [9]. In addition to its effects on VEGF, STAT3 has
been implicated as a facilitator of angiogenesis by other
mechanisms. For example, it has recently been demonstrated that
STAT3 regulates expression of both MMP-2 and MMP-9,
important facilitators of both angiogenesis and metastasis [10]. It
has been reported also that STAT3 is required for endothelial cell
migration and microvascular tube formation [11]. These data
implicate STAT3 as a key facilitator of angiogenesis beyond
regulation of VEGF. Importantly, it has been demonstrated that
STAT3 is critical for expression of HIF-1a, the best-documented
transcriptional activator of VEGF and a wide variety of other
angiogenic and invasive genes. STAT3 is thus an attractive
molecular target for the development of novel anti-angiogenesis
therapy. Several strategies have been already reported to block the
action of STAT3 pathway, including antisense methods, inhibition
of upstream kinases, phosphotyrosyl peptides or small molecule
inhibitors [1,12,13]. In our study we used LLL12, a potent small
molecule considered to block STAT3 dimerization and prevent
STAT3 being recruited to the receptors and thus block JAK and
possibly Src kinase-induced phosphorylation of STAT3. In the
present study, we investigated the direct effect of LLL12 on
angiogenesis in vitro and in vivo, and its antitumor activity against
an established osteosarcoma xenograft model. Our findings clearly
indicate that LLL12 directly inhibits tumor angiogenesis both in in
vitro and in vivo models. In vivo, LLL12 significantly decreased
growth of an osteosarcoma xenograft model. The antitumor
activity of LLL12 was associated with decreased microvessel
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complete abrogation of phosphorylated STAT3 protein.
Results
LLL12 inhibits cellular viability/migration/invasion in
human endothelial cells as well as viability of smooth
muscle cells
The small molecule inhibitor of STAT3, LLL12, has previously
been shown to inhibit cellular proliferation and migration in
several human malignant breast, pancreas and glioblastoma cells
lines (IC50 concentrations ranging from 0.16–3.09 mM) [14],
however inhibition of angiogenesis by this compound has not been
investigated. To test in vitro anti-angiogenic activity of LLL12, we
examined whether LLL12 inhibited proliferation of human
umbilical vascular endothelial cells (HUVECs). Cells were
stimulated with VEGF in the absence or presence of LLL12 and
cell number determined after 2 days. As shown in Figure 1A,
LLL12 inhibited proliferation in a concentration-dependent
manner with .70% inhibition at 100 nM concentration. Two
further assays demonstrated similar effects of LLL12 on invasion
through Matrigel coated membranes, and in a wound-healing
assay for migration (Figure 1B). Vascular smooth muscle cells
(HASMCs), one of the major cell types of the vascular wall, play a
critical role in the process of angiogenesis, under both physiolog-
ical and pathophysiological conditions, including the cancer
microenvironment. Therefore we performed a cell proliferation
assay using HASMCs. LLL12 significantly inhibited proliferation
of HASMCs at 100 nM concentration (data not shown).
LLL12 inhibits VEGF-induced STAT3 phosphorylation and
tube formation in HUVECs
The results above indicate that LLL12 inhibits HUVEC
proliferation and migration at ,100 nM. To determine whether
this effect correlated with inhibition of STAT3 phosphorylation,
HUVECs were grown under serum-deficient conditions and
stimulated with VEGF (10 ng/ml) or PBS (control), and
phosphorylated STAT3 determined after 18 hrs of LLL12
treatment. As shown in Figure 2A, VEGF-induced robust STAT3
phosphorylation in HUVEC cells, which supports the previous
reports where in aortic macrovascular endothelial cells STAT3 is
tyrosine phosphorylated in response to VEGF [15]. LLL12
treatment abolished VEGF-induced phosphorylation of STAT3
at drug concentrations that blocked VEGF-induced proliferation
(Figure 2A). To examine whether LLL12 inhibited ‘capillary
tube’ formation, HUVECs were grown under serum-deficient
conditions and stimulated with VEGF or PBS (control). LLL12 at
100 nM concentration significantly inhibited formation of capil-
lary-like structures (Figure 2B), indicating that signaling through
STAT3 is necessary for VEGF-stimulated proliferation and tube
formation of these endothelial cells.
Inhibition of STAT3 disrupts the F-actin and microtubule
cytoskeletal elements in HUVEC cells
Previous reports have shown that cytosolic STAT3 acts as a co-
regulator of F-actin fiber [16] and microtubule [17] formation.
Since LLL12 significantly reduced migration of HUVEC cells
therefore, we hypothesized that disruption of lamellipodia
formation at the leading edge, due to reduced Rac1 activity a
downstream target in the STAT3 pathway, and microtubule
breakdown at the trailing edge, may account for this phenomenon.
To test this, HUVEC cultures were treated with VEGF alone,
VEGF plus DMSO (drug vehicle) or VEGF with LLL12 (100 nM)
for 18 hrs. After staining for F-actin and b-tubulin, HUVEC
cultures treated with VEGF (10 ng/mL), or VEGF and the drug
vehicle, DMSO, showed a greater number of cells than those
treated with PBS (Figure 3). The F-actin in the control and
VEGF-treated cultures produced thin, uniform fibers spanning the
length of the cells, with a greater localization at the peripheral
lamellipodia and intercellular junctions. The microtubules formed
a dense lattice that emanated from the center of the cells, and
extended to the periphery of the cells in a generally linear manner.
However, in STAT3 inhibited cultures, the cells had a condensed,
rounded morphology, compared to VEGF treated cultures. The F-
actin had condensed into fewer fibers, and, most strikingly, was
completely absent from the leading edges of the cells (white
arrows, Figure 3). The microtubule structures were additionally
affected by the LLL12 treatment. As highlighted by the
arrowheads in Figure 3, b-tubulin staining still showed that the
microtubules emanated from the nuclear region of the HUVEC
cells, but at the periphery, they curled over, unable to extend to
the leading edge.
LLL12 is a potent Inhibitor of Angiogenesis in Vivo
Because in HUVECs LLL12 was observed to be both anti-
migratory and proliferative in vitro (Figures. 1, and 2), its effect on
angiogenesis in vivo was investigated using a Matrigel plug assay.
To directly test the anti-angiogenic activity of LLL12 in vivo, mice
were implanted subcutaneously with Matrigel plugs infused with
PBS or VEGF. Mice were treated with LLL12 (2.5 and 5 mg/kg
by I.P administration) immediately after implantation of the plug
and once daily for 7 days. Plugs were excised at day 7 and
angiogenesis quantified as described in Materials and Methods.
VEGF increased the number of vessels detected in Matrigel plugs
by .10-fold over that in PBS infused (control) plugs. LLL12
reduced vessel formation at 2.5 mg/kg and significantly (by
,75%) at 5 mg/kg dose level compared to controls (Figure 4).
LLLL12 inhibits tumor angiogenesis and tumor growth in
Osteosarcoma Xenografts
We examined the inhibitory function on tumor growth by
LLL12 using an osteosarcoma xenograft model. Growth of control
(no treatment) or vehicle treated OS-1 xenografts was highly
reproducible (Figure 5A). Mice were terminated when tumors
grew to a volume four-fold greater than the volume at the start of
treatment, usually after 3 to 4 weeks, and tumors were snap-frozen
for biochemical determinations. LLL12 was administered at
5 mg/kg (based on the dose having the greatest anti-angiogenic
effects) was well tolerated with no mortality. In LLL12 treated
mice there was a period of continued growth (2 weeks) followed by
complete tumor stasis for the remaining 4 weeks of treatment. As
shown in Figure 5A, after a 6 weeks the mean tumor volume of
LLL12-treated group were significantly less than that of control or
DMSO group at time of termination (P,0.01).
To examine the pharmacodynamic effects of LLL12, total and
phospho-STAT3, Ki67 and CD34 staining as well as apoptosis
(TUNEL) were determined in control, vehicle alone (DMSO) and
LLL12 treated tumors at the end of treatment or when tumors
reached 4-times the initial volume (controls). As shown in
Figure 5B, robust phospho-STAT3 was detected in all control
or DMSO treated tumors, in contrast after 6 weeks of treatment
with LLL12 no phospho-STAT3 could be detected, although total
STAT3 was unchanged compared to controls. To evaluate the
effect of LLL12 on tumor angiogenesis, 5-mm tumor sections were
stained with anti-CD34 antibody. The average vessel number in
LLL12–treated group was dramatically decreased compared to
control or DMSO treated groups (Figure 6A), indicating that
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35513Figure 1. LLL12 inhibits angiogenesis in vitro. HUVECs were grown under serum-deficient conditions and stimulated with VEGF (10 ng/ml) in
the absence or presence of LLL12 (100 nM). A. Proliferation/viability was determined after 2 days by Calcein AB staining. Migration was determined
using the crystal violet assay as described in Materials and Methods as well as scratch assay/wound-healing. Invasion was determined using Matrigel
coated membranes (photomicrographs show representative fields) and is quantified (bottom right panel). Each data set represents the mean 6 SE for
at least 3 independent experiments. B. To study the effect of LLL12 (100 nM) on the cell migration in HUVEC cells, wound-healing assays were carried
out by allowing the cells to move to the scar region for 24 hours using VEGF (10 ng/ml) as a positive control in the presence and absence of LLL12
(original magnification 640).
doi:10.1371/journal.pone.0035513.g001
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lower frequency of proliferating cells (Ki67-positive) in LLL12
treated tumors compared to control and DMSO treated groups
(Figure 6B). However, LLL12 treatment did not increase the
incidence of TUNEL-positive cells, suggesting the action of this
drug against OS-1 xenografts is largely cytostatic (Figure 6C).
LLL12 inhibits not only VEGF but also other important
factors for new vessel formation in OS-1 xenografts
Previous reports indicate that in addition to its effects on VEGF,
STAT3 facilitates angiogenesis by other mechanisms. To examine
whether targeting STAT3 by LLL12 inhibits not only VEGF but
also other critical angiogenic factors in osteosarcoma tumors, we
examined the levels of 55 angiogenesis-associate proteins using a
human angiogenesis array. We analyzed the array data in
osteosarcoma tumors. Antibody array studies of the osteosarcoma
tumor lysates were derived from control and treated groups
discussed above. Relative to control OS-1 xenografts, LLL12
treated tumors showed a dramatic decrease of VEGF, MMP-9,
Angiopoietin, tissue factor (TF) and FGF-1 (Figure 7), critical
regulators of angiogenesis (Michael et al 1991). We used the
Pediatric Preclinical Testing Program (PPTP) expression data set
[18] for pediatric tumor xenografts (http://pptp.nchresearch.org/
data.html) to examine the expression of human angiogenic genes
in osteosarcomas relative to other pediatric solid tumor and
leukemia models. Osteosarcoma xenografts express high levels of
VEGF-A, angiopoetin 1, Tissue Factor and MMP9, relative to
leukemia xenografts. Expression of angiopoeitin 1 was generally
higher in osteosarcoma xenografts than in most other pediatric
solid tumors, whereas among the osteosarcoma xenografts FGF1
was expressed most highly in the OS-1 model.
LLL12 directly inhibits growth of sarcoma cell lines
We examined direct effects of LLL12 on sarcoma cell
proliferation. Tumor cells were exposed to LLL12 (1–10
4 nM)
for approximately four cell divisions and viability was determined
by Alamar Blue staining. Of interest the human osteosarcoma line,
OS-17 and the canine osteosarcoma cell line, Abrams) were more
sensitive than either Rh30 (rhadomyosarcoma) or EW8 (Ewing
sarcoma) human cell lines, Table 1.
Figure 2. Inhibition of angiogenesis by LLL12 correlates with inhibition of STAT3 phosphorylation. A) Suppression of STAT3
phosphorylation by LLL12 in HUVEC cells after VEGF (10 ng/ml) stimulation. HUVEC cells were grown and stimulated with VEGF (10 ng/ml) for
10 mins and treated with LLL12 for 18–20 hrs. Total cellular protein was extracted and both total STAT3 and pSTAT3(Tyr705) expression was
determined. GAPDH was used as a loading control. B) LLL12 inhibits HUVEC tube formation. HUVECs were grown in M200, and incubated with PBS or
VEGF (10 ng/ml) for 18–20 hr in the absence or presence of LLL12 (100 nM). Tube formation was quantified as described in Materials and Methods.
doi:10.1371/journal.pone.0035513.g002
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LLL12 is a novel small molecule allosteric inhibitor of STAT3,
thought to bind STAT3 monomers at the tyrosine 705-
phosphorylation site and to prevent dimerization and activation.
Previous work has established that LLL12 inhibits proliferation of
various cancer cells in vitro, and tumor growth of both breast and
glioblastoma xenograft models [14]. Moreover, LLL12 induces
apoptosis in medulloblastoma and glioblastoma cells and was also
able to inhibit colony formation, wound healing and decreased IL-
6 and LIF secretion [19]. Antisense STAT3 oligonucleotide or
STAT3 inhibitors, other than LLL12, have been shown to reduce
microvessel density in tumor models [20,21]. However, the
mechanism for these anti-angiogenic effects has not been
investigated. Our current work shows that at concentrations of
drug that abrogate STAT3 phosphorylation, LLL12 blocks
angiogenesis, and suppresses tumor vasculature in osteosarcoma
tumors.
The direct effect of LLL12 suppressing proliferation of HIVEC
and HASMCs was shown at low concentrations of drug that
completely suppressed VEGF-stimulation of STAT3 phosphory-
lation. LLL12 also potently inhibited HUVEC migration and
invasion at this concentration, suggesting that STAT3 signaling is
intimately involved in these processes. LLL12 exerted marked
effects on both F-actin fibers and microtubules in HUVECs. In
treated cells, F-actin had condensed into fewer fibers, and was
completely absent from the leading edges of the cells. Similarly,
microtubule structures emanated from the nuclear region, but at
the periphery, they curled over, unable to extend to the leading
edge. These observations substantiate that STAT3 is a necessary
Figure 3. The STAT3 inhibitor, LLL12, induces cytoskeletal changes in cultured HUVEC cells. HUVEC cells cultured in 4-well chamber
slides were treated with PBS, VEGF (10 ng/mL) alone, VEGF with DMSO or LLL12 (100 nM) for 18 hrs. The cultures were then probed using anti-b-
tubulin primary antibodies (green), and F-actin was stained using phalloidin (red). White arrows highlight F-actin localization at the leading edge,
while white arrowheads indicate the curling of microtubules at the cell periphery. 2006magnification. Slice depth=1 mm. Scale bar=20 mm. Inset
4006magnification.
doi:10.1371/journal.pone.0035513.g003
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RhoA stabilization of already formed actin fibers was largely
unaffected. They further show that without F-actin at the
periphery, the cells are unable to grow and/or migrate, and that
the structural microtubules cannot extend to the leading edges,
further compounding the effects of STAT3 inhibition. Together,
these effects account for the reduction of HUVEC cell migration
shown previously.
In vivo, VEGF stimulated vascular cell invasion ,10-fold over
that of PBS-infused Matrigel. Daily treatment with LLL12,
starting immediately after Matrigel plug implantation, showed a
significant, dose-dependent, inhibition of CD34-positive cells into
the VEGF-infused Matrigel plugs, confirming that the effects seen
in vitro could be recapitulated at tolerable dose levels of drug in
vivo.
We subsequently investigated the activity of LLL12 against a
human osteosarcoma xenograft model, OS-1. Treatment with
LLL12 was started against established xenografts (median volume
200 mm
3). Interestingly, tumor growth was maintained at rates
similar to control tumors (no treatment or drug vehicle only) for
two weeks. Subsequently, further treatment resulted in complete
tumor growth inhibition. The results for LLL12 differ from
previous results with angiogenesis inhibitors, cedirinib and
sunitinib [5,22], or sorafenib (unpublished data). Cedirinib and
sorafenib induced complete growth stasis from initiation of
treatment, whereas sunitinib significantly retarded the rate of
OS-1 growth from start of treatment. The reason behind this
relatively slow onset of tumor growth retardation is not known, but
may relate to rapid clearance of LLL12 from plasma (unpublished
data), and slow accumulation of drug into tumor tissue. However,
analysis of phospho-STAT3 in tumors at the end of 6 weeks
treatment showed complete abrogation of signal compared to
robust phosphor-STAT3 detected in control tumors at the time
the mice were euthanized. The rate of proliferation (Ki67 positive
cells) of OS-1 tumors was significantly reduced, as was microvessel
density, consistent with an angiogenic effect of LLL12. In contrast,
there was no significant change in the frequency of apoptotic cells
as judged by TUNEL staining, suggesting the effect of LL12 is
largely cytostatic in this tumor model.
Our data indicate that STAT3 inhibition effectively suppresses
growth of OS-1 osteosarcoma xenografts. LLL12 appears to have
both direct and indirect effects on angiogenesis. Firstly, LLL12
inhibits proliferation of vascular elements by blocking the response
to VEGF in vitro and in vivo. LLL12 inhibited VEGF-stimulated
phosphorylation of STAT3 at a concentration similar to that
blocking proliferation, migration and capillary tube formation in
HUVECs, suggesting that STAT3 signaling is important in these
processes. Secondly, LLL12 reduced tumor-associated angiogenic
factors (VEGF, MMP-9, angiopoetin, TF and FGF1), probably as
a direct consequence of STAT3 inhibition in tumor cells. Whether
inhibition of STAT3 in OS-1 tumor cells directly inhibits
proliferation is not known. OS-1 grows only as a xenograft, and
there is no isogenic cell line model in vitro. However, LLL12 does
directly inhibit growth of human carcinoma cell lines with IC50
concentrations in the 1–5 mM range [14]. LLL12 potently
inhibited proliferation of OS17 and also the canine osteosarcoma
model. In contrast, the other sarcoma cell lines (Rh30 and Ew8)
were 6–10-fold less sensitive. It is thus likely that inhibition of
STAT3 signaling by LLL12 inhibits tumor growth through a
combination of its direct and indirect effects on angiogenesis and
direct inhibitory effect on tumor cell proliferation.
Materials and Methods
Reagents
M200, M231, media, fetal bovine serum (FBS) and Calcein
Alamar Blue (Calcein AB) were purchased from Invitrogen
(Carlsbad, CA). Low serum growth supplement (LSGS) and
Smooth Muscle Growth Supplement (SMGS) was obtained from
Cascade Biologics Inc (Portland Oregon). Endothelial Tube
formation assay kits were from Cell Biolabs, Inc. (San Diego,
CA). Growth factor reduced Matrigel for in vivo experiments and
precoated Matrigel inserts for invasion assays were purchased from
BD Biosciences (Palo Alto, CA). Anti-CD34 antibody (ab27448)
was from Abcam (Cambridge, MA, USA). LLL12 (5-Hydroxy-
9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide) was synthe-
sized in the Laboratory of Dr Pui-Kai Li (College of Pharmacy,
The Ohio State University). The powder was dissolved in sterile
Figure 4. LLL12 inhibits angiogenesis in mice. Matrigel plugs containing PBS (Control), or VEGF (100 ng/ml) were implanted subcutaneously in
mice that were or were not treated with LLL12 (5 mg/kg daily). The Matrigel plugs were excised on day 7, fixed with formalin and 5-mm sections were
stained for CD34 staining. The numbers of CD34 positive vessels per high power field (HPF, magnification, 2006) were counted for each experimental
condition. Results are mean (n=4) 6 SE. *P,0.05; versus VEGF alone.
doi:10.1371/journal.pone.0035513.g004
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Aliquots of the stock solution were stored at 220uC.
Cell Culture
Human umbilical vein endothelial cells (HUVEC) were
obtained from the American Type Culture Collection (ATCC).
All experiments were done using endothelial cells between
passages 3 and 8. HUVECs were maintained in endothelial cell
growth medium M200 (Invitrogen) in high glucose supplemented
medium with 15% FBS, endothelial cell growth supplements
(LSGS Medium, Cascade Biologics), and 2 mM glutamine at
37uC with 5% CO2. All cells were maintained as sub confluent
cultures and split 1:3, 24 hours before use. Primary human aortic
smooth muscle cells (HASMC) were obtained from Cascade
biologicals and all experiments were done using HASMC between
passages 3 and 8. HASMC were maintained in M231 (Invitrogen).
To induce differentiation of normal human vascular smooth
muscle cells, Medium 231 was supplemented with Smooth Muscle
Differentiation Supplement (Invitrogen) and cells were incubated
at 37uC with 5% CO2.
Western blotting
Cell lysis, protein extraction and immunoblotting were as
described previously (Kurmasheva et al 2009,). We used primary
antibodies to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), pSTAT3 (Tyr 705) and STAT3 (Cell Signaling).
Immunoreactive bands were visualized by using Super Signal
Chemiluminiscence substrate (Pierce) and Biomax MR and XAR
film (Eastman Kodak Co.). Fonly ifteen mL of total volume and
20 mg protein sample was resolved on a 4–12% SDS-polyacryl-
amide gel. Proteins were transferred to a PVDF membrane and
immune-detection was performed with specific primary antibod-
ies.
Figure 5. LLL12 inhibits tumor growth in vivo by inhibition of STAT3. A, LLL12 inhibits tumor growth in osteosarcoma xenograft
mice. OS-1 tumors were transplanted into 6-week-old CB17SC scid2/2 female mice. After tumors grew to ,130 mm
3, mice were randomized to
receive no treatment (control), DMSO or LLL12 (5 mg/kg/d) for a planned six weeks. LLL12 inhibited tumor growth as measured by tumor volume.
Representative tumors at the termination of each group are shown. B. Western blot showing STAT3, and p-STAT3 level in six independent tumors
from each treatment group. LLL12 completely blocks pSTAT3 levels with compassion to control and DMSO control group.
doi:10.1371/journal.pone.0035513.g005
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The Endothelial Tube Formation Assay (CBA200, Cell Biolabs
Inc., San Diego, CA, USA) was used in addition to the HUVEC
proliferation assay. The ECM gel was thawed at 4uC and mixed to
homogeneity using cooled pipette tips. Cell culture plates (96-well)
were bottom-coated with a thin layer of ECM gel (50 ml/well),
which was left to polymerize at 37uC for 60 min. HUVEC (2–
3610
4 cells) were stimulated with VEGF in 150 ml medium and
added to each well on the solidified ECM gel. Culture medium
was added to each well in the presence or absence of LLL12. The
plates were incubated at 37uC for 12–18 hr and the endothelial
tubes were quantified using a fluorescent microscope after staining
with Calcein AM. Three microscope fields were selected at
random and photographed. Tube forming ability was quantified
by counting the total number of cell clusters (knots) and branches
under a 46objective and four different fields per well. The results
are expressed as mean fold change of branching compared with
the control groups. Each experiment was performed at least three
times.
Cell viability/proliferation assay
HUVECs and HASMCs were seeded on 6-well plates at a
density of approximately 1610
5 cells/well in their respective
media. Cells were treated with 100 nM of LLL12 one day after
seeding. After two days, Calcein AB was added directly into
culture media at a final concentration of 10% and the plates were
incubated at 37uC. Optical density (OD) was measured spectro-
photometrically at 540 and 630 nm with at 3–4 h after adding
Calcein AB. As a negative control, Calcein AB was added to
medium without cells. To determine sensitivity to LLL12 of
sarcoma cell lines, cells were exposed to increasing concentrations
of LLL12 for approximately four cell divisions, depending on the
rate of proliferation of each cell line.
Quantitative migration assay
HUVECs were grown in M200 containing LSGS until 40–50%
confluent. Cells were washed with PBS, trypsinized for 5–10 min,
collected with 0.2% FBS and centrifuged at 300 g for 5 min. Cells
were then resuspended with 0.2% FBS and counted using a
Beckman Coulter Z2. A volume of 400 ml of this mix containing
5610
5 cells was placed on to Boyden Chambers (8 mm pore)
inserts with and without LLL12 (100 nM) in 24 well plates with
500 ml of M200. VEGF (R and D Systems) in 1% BSA was added
to a final concentration of 10 ng/ml in the lower chambers as a
chemo-attractant. Cells were pretreated with antibody for 30 min
in suspension, then placed in the chambers and incubated at 37uC
Figure 6. LLL12 inhibits angiogenesis in OS-1 xenografts. Analysis of vascularity and tumor cell proliferation: Tumors were harvested at
completion of the study and examined by hematoxylin and eosin staining. Vascularity of osteosarcoma tumor xenografts in mice was evaluated by
CD34 related antigen staining (brown) for endothelial cells, and Ki 67 for proliferation. Apoptotic cells were identified by TUNEL staining. There isa
significant effect of LLL12 as compared to vehicle control on tumor vasculature as well as cell proliferation (quantified by staining with anti–Ki-67) in
osteosarcoma xenografts, but no significant change in apoptosis in drug treated tumors. All values are expressed as mean plus or minus SEM. *P,.01
by Student t test.
doi:10.1371/journal.pone.0035513.g006
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were then blotted and fixed with 3.7% formaldehyde containing
0.05% crystal violet for 30 min. After repeated washes with
distilled water the membranes were air-dried. The migrated cells
on the bottom side of the membranes were collected by scraping
the bottom of the chamber with a Q-tip, which was subsequently
placed into a 1.5 ml eppendorf tube and incubated in 80%
methanol to extract the dye. The remainder of the cells on top of
the membrane and within the Boyden chamber, were separately
incubated in 80% methanol, shaken at 500 rpm for 30 min, and
the extracted dye measured at 570 nm. Migration was quantified
using the ratio of the migrated cells over the total cells (migrated
plus remaining cells) to determine the fraction of migrating cells in
each individual experiment. Experiments were performed in
duplicate on multiple occasions as described in the figure legends.
Cell migration assay (in vitro wound-healing assay)
HUVEC migration was monitored using the wound-healing
assay described by Thaloor et al. [23]. Briefly, 3610
4 cells/well/
ml were seeded in 24-well plates using M200 medium with LSGS.
After cells had attached and form a monolayer on plates
completely, we scraped the cells with same width using yellow
tip. After scraped, the cells were washed with PBS and were
incubated with the medium containing VEGF (10 ng/ml)) with or
without LLL12 (100 nM). Width was photographed at different
time intervals (0 and 24 hours) with a magnification of 406with a
microscopic camera system (Leitz Diavert microscope, Leica,
Bensheim; AxioCam, Carl Zeiss, Gottingen, Germany).
Invasion Assay
The Matrigel invasion assays were carried out using Matrigel
precoated inserts (BD Bioscience) following the manufacturer’s
instructions. Six hundred ml of M200 medium with or without
VEGF (20 ng/ml, R&D Systems) was placed in the lower wells.
Proliferating HUVECs (4610
5 cells/ml) were pretreated with
LLL12 (100 nM) and 100 ml of cell suspension was loaded into
each of the upper wells. The chambers were incubated for 18–
20 hr at 37uC. After incubation, the inserts were removed, and the
non-invading cells on the upper surface were removed with a
cotton swab. The cells on the lower surface of the membrane were
fixed in 100% methanol for 15 minutes, air-dried, and stained
with Diff-Quik stain for 2 min. The cells were counted in six
individual high-power fields for each membrane condition under a
light microscope. Assays were performed in triplicate for each
treatment group and the results were expressed as migrated cells
per field for each condition [24].
Vascularization of Matrigel
TM Plugs in vivo
To further characterize anti-angiogenetic properties of LLL12 in
vivo,weperformedmurineMatrigelplugexperiments.PBSwasused
as a negative control, and VEGF (100 ng/mL) as a positive control.
Matrigel was injected subcutaneously into CB17SC scid
2/2 female
mice, forming semi-solid plugs. Animals received treatment of
LLL12 (5 mg/kg) I.P. intraperitoneal (i.p.) injection immediately
after the Matrigel injection and daily for 7 days. On day 7, plugs
were excised under anesthesia, fixed in PBS-buffered 10% formalin
containing 0.25% glutaraldehyde, and were processed for H & E
and Masson’s Trichrome staining. Vascular identity of the
infiltrating cells was established with CD34 immunostaining. The
regions containing the most intense area of neovascularization
(‘‘hotspots’’) were chosen for analysis. Eight hotspots were identified
for each Matrigel or tumor section. The ImagePro Plus analysis
system (MediaCybernetics Inc,Bethesda, MD)wasused to quantify
the percentage of area occupied by the vessel-like structures in each
field. The mean 6 SE from each group were compared. The
negative control was obtained by tissue staining with secondary
antibody only.
In Vivo Tumor Growth Inhibition Studies
CB17SC-F scid2/2 female mice (Taconic Farms, German-
town, NY) were used to propagate subcutaneously implanted OS-
1 osteosarcoma tumors [25,26]. All mice were maintained under
Figure 7. LLL12 downregulates several angiogenic factors.
LLL12 induced changes in angiogenic factors in OS-1 xenografts were
determined using a Proteome profiler antibody array as described in
Materials and Methods. The effect of LLL12 treatment is quantified in
the histogram, untreated tumors (2), tumors from mice receiving LLL12
(+), 5 mg/kg).
doi:10.1371/journal.pone.0035513.g007
Table 1. Sensitivity of sarcoma cell lines to LLL12.
Cell Line IC50 (mM) ± St. Dev
EW8 2.360.31
Rh30 1.460.25
OS17 0.2360.03
Abrams 0.04460.002
doi:10.1371/journal.pone.0035513.t001
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protocols and conditions approved by the institutional animal
care and use committee of the appropriate consortium member.
Mice were randomized into groups of 10 when tumors were 100 to
200 mm
3. LLL12 was administered by intraperitoneal (i.p.)
injection at indicated dose levels every day, for 6 weeks. Tumor
volumes were determined as previously described [26].
Ethics Statement
All animal experiments were conducted in accordance with
institutional animal care and use committee of the The Research
Institute at Nationwide Children’s Hospital approved protocols,
designed to minimize the numbers of mice used and to minimize
any pain or distress. The named institutional review board or
ethics committee specifically approved this study.
Immunohistochemistry (IHC)
For IHC, fixed tumors were sectioned at 5-mm then dewaxed
and soaked in alcohol. After microwave treatment in antigen
unmasking solution (Vector Laboratory, Burlingame, CA, USA)
for 10 min, endogenous peroxidase activity was inactivated by
incubating in 3% hydrogen peroxide (H2O2) for 15 min and
sections were incubated with primary antibody in phosphate-
buffered saline at 4uC overnight. After washing with phosphate-
buffered saline (PBS), immuno-staining was performed using the
Vectastain Universal Quick Kit and DAB Peroxidase Substrate
Kit (Vector Laboratories, Burlingame, CA, USA) according to the
manufacturer’s instructions. Antiserum was omitted in the
negative control. The number of cells staining positive was
counted by a blinded observer in 5 random 406fields and treated
versus controls compared (Student t test). Images were obtained
with an Olympus AX70 fluorescence microscope and Spot v2.2.2
(Diagnostic Instruments, Sterling Heights, MI) digital imaging
system. Apoptosis was detected in deparaffinized tumor sections by
TdT-mediated dUTP nick-end labeling (TUNEL) assay using the
in situ cell death detection kit (Cat no. Cat. No. L00297,
GenScript USA Inc) according to manufactures instructions.
Confocal Microscopy
HUVEC cells were grown in Lab-Tek 4-well chamber slides
(Nunc/Thermo Scientific) to approximately 60% confluence, and
treated with PBS, VEGF (10 ng/mL) DMSO with VEGF, or
100 nM LLL12 for 18 hrs with VEGF. The cultures were fixed in
cold 4% paraformaldehyde for 20 mins at 4uC, and then cells
were permeabilized in 0.1% Triton X-100 (Sigma-Aldrich). The
cells were probed using 10 mg/mL mouse anti-human b-Tubulin I
primary antibody (Sigma-Aldrich, clone TUB 2.1) overnight at
4uC, and then stained using 10 mg/mL goat anti-mouse Alexa
FluorH 488 conjugated F(ab’)2 (Invitrogen) for 1 hr. at RT. F-actin
in the cells was stained at RT for 1 hr. using 4 U/mL Alexa
FluorH 633 conjugated phalloidin (Invitrogen). The cells nuclei
were then stained by incubating with 300 nM 49,6-diamidino-2-
phenylindole (DAPI) dilactate (Invitrogen) for 5 mins at RT.
Samples were washed 4 times in PBS after each step during
processing. After mounting a coverslip, 102461024 pixel images
were taken using a Zeiss Axiovert 710 confocal microscope with a
slice depth of 1 mm. Image processing was performed using the
Zeiss Image Browser software package.
Human Angiogenesis Array
Proteome profiler antibody array (R & D systems; Cat no
ARY007, Minneapolis, MN) was used according to manufactur-
er’s instructions to detect the relative levels of expression of 55
angiogenesis related proteins in control and treated tumors. After
blocking the membranes 300 mg of protein from the tumor tissue
lysate from control and LLL12 treated groups were added and
incubated for overnight at 4uC. Next day the membranes were
washed and streptavidin-HRP was added or 30 minutes. Immu-
noreactive signals were visualized by using Super Signal
Chemiluminiscence substrate (Pierce) and Biomax MR and
XAR film (Eastman Kodak Co.). Array data on developed X-
ray film was quantified by scanning the film using Biorad
Molecular Image Gel Doc
TM XR+ and analyze the data using
Image Lab
TM software.
Statistical analysis
Significance of correlations was done using GraphPad Prism
software. Unpaired t tests were used for all analyses assuming
Gaussian populations with a 95% confidence interval. Data are
presented as mean 6 SE. Differences were analyzed with the
Student t test, and significance was set at P less than ,0.05.
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